Company Profile

Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. These diseases include diabetes, rare cancers including brain (glioblastoma), ovarian, liver and pancreatic cancer and neurological/ophthalmologic conditions. Midatech�s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies. Midatech�s core product candidates derive from its two multi-applicable platform technologies that can be used alone or in combination to enable the targeted delivery (�right place�) and controlled release (�right time�) of existing drugs. These technologies are provided through its wholly-owned subsidiaries, Midatech and Q-Chip (acquired in 2014). Midatech�s core platform is a drug conjugate delivery system based on a patented form of gold nanoparticles (GNP) combined with existing drugs for the safe and targeted release of therapeutic payloads at specific organs, cells or sites of disease. The Group�s second platform is a sustained release technology acquired with Q Chip that involves the consistent and precise encapsulation of active drug compounds within polymer microspheres enabling their release into the body in a highly controlled manner over a prolonged period of time. On 4 June 2015, Midatech announced a proposed acquisition of DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company, based in Raleigh, NC. The acquisition brings a portfolio of marketed oncology products and a salesforce in US to Midatech and is expected to complete in H2 2015. The Group is headquartered near Oxford, UK, with a nanoparticle manufacturing operation in Bilbao, Spain and an R&D facility in Cardiff, UK.